Guangdong University of Technology, Institute for Biomedical and Pharmaceutical Sciences, Guangzhou, 510006, China.
School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.
AAPS PharmSciTech. 2019 Jan 9;20(2):64. doi: 10.1208/s12249-018-1208-8.
Spherical poly (D, L-lactic-co-glycolic acid) microparticles (PLGA-MPs) have long been investigated in order to achieve sustained delivery of proteins/peptides. However, the formation mechanism and release characteristics of the specific shape MPs were still unknown. This study aimed to develop a novel-dimpled exenatide-loaded PLGA-MPs (Exe-PLGA-MPs) using an ultra-fine particle processing system (UPPS) and investigate the formation mechanism and release characteristics. Exe-PLGA-MPs were prepared by UPPS and optimized based on their initial burst within the first 24 h and drug release profiles. Physicochemical properties of Exe-PLGA-MPs, including morphology, particle size, and structural integrity of Exe extracted from Exe-PLGA-MPs, were evaluated. Furthermore, pharmacokinetic studies of the optimal formulation were conducted in Sprague-Dawley (SD) rats to establish in vitro-in vivo correlations (IVIVC) of drug release. Exe-PLGA-MPs with dimpled shapes and uniform particle sizes achieved a high encapsulation efficiency (EE%, 91.50 ± 2.65%) and sustained drug release for 2 months in vitro with reduced initial burst (20.42 ± 1.64%). Moreover, the pharmacokinetic studies revealed that effective drug concentration could be maintained for 3 weeks following a single injection of dimpled Exe-PLGA-MPs with high IVIVC. Dimpled PLGA-MPs prepared using the UPPS technique could thus have great potential for sustained delivery of macromolecular proteins/peptides.
球形聚(D,L-乳酸-共-乙醇酸)微球(PLGA-MPs)长期以来一直被研究用于实现蛋白质/肽的持续递送。然而,特殊形状 MPs 的形成机制和释放特性仍然未知。本研究旨在使用超精细颗粒处理系统(UPPS)开发新型有凹坑的艾塞那肽负载 PLGA-MPs(Exe-PLGA-MPs),并研究其形成机制和释放特性。通过 UPPS 制备 Exe-PLGA-MPs,并根据其在最初 24 小时内的初始突释和药物释放曲线对其进行优化。对 Exe-PLGA-MPs 的理化性质进行评价,包括形态、粒径和从 Exe-PLGA-MPs 中提取的 Exe 的结构完整性。此外,在 Sprague-Dawley(SD)大鼠中进行最佳配方的药代动力学研究,以建立药物释放的体外-体内相关性(IVIVC)。具有凹坑形状和均匀粒径的 Exe-PLGA-MPs 实现了高包封效率(EE%,91.50±2.65%)和体外 2 个月的持续药物释放,初始突释减少(20.42±1.64%)。此外,药代动力学研究表明,通过单次注射凹坑 Exe-PLGA-MPs 可维持 3 周的有效药物浓度,具有较高的 IVIVC。因此,使用 UPPS 技术制备的凹坑 PLGA-MPs 可能具有用于持续递送大分子蛋白质/肽的巨大潜力。